Soleno Therapeutics Inc (SLNO) — Cash Flow-to-Debt Ratio
Soleno Therapeutics Inc (SLNO) has a Cash Flow-to-Debt Ratio of 0.23x as of March 2026, meaning its operating cash flow of $25.98 Million could theoretically repay 0% of its total liabilities ($112.59 Million) in one year. See SLNO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Soleno Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Soleno Therapeutics Inc across 14 annual periods. Also explore how fast is Soleno Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Soleno Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Soleno Therapeutics Inc. For market capitalisation and broader financial context, see SLNO stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | $46.80 Million | $113.72 Million | ▲ +151.1% |
| 2024 | -0.80x | $-69.10 Million | $85.86 Million | ▲ +25.2% |
| 2023 | -1.08x | $-24.94 Million | $23.18 Million | ▲ +16.4% |
| 2022 | -1.29x | $-20.78 Million | $16.15 Million | ▲ +17.7% |
| 2021 | -1.56x | $-27.77 Million | $17.76 Million | ▼ -20.5% |
| 2020 | -1.30x | $-25.22 Million | $19.43 Million | ▼ -73.5% |
| 2019 | -0.75x | $-17.38 Million | $23.23 Million | ▲ +18.4% |
| 2018 | -0.92x | $-11.68 Million | $12.74 Million | ▼ -15.1% |
| 2017 | -0.80x | $-9.95 Million | $12.49 Million | ▲ +87.4% |
| 2016 | -6.34x | $-13.50 Million | $2.13 Million | ▼ -206.3% |
| 2015 | -2.07x | $-10.30 Million | $4.98 Million | ▼ -764.2% |
| 2014 | -0.24x | $-4.48 Million | $18.73 Million | ▼ -967.1% |
| 2013 | -0.02x | $-885.22K | $39.45 Million | ▲ +76.4% |
| 2012 | -0.10x | $-3.50 Million | $36.71 Million | — |